[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:orexin-a":3},{"name":4,"total":5,"recruiting":5,"trials":6},"Orexin A",3,[7,15,21],{"nct_id":8,"title":9,"phases":10,"status":12,"updated_at":13,"content_modified":14},"NCT07540897","A Study to Evaluate the Efficacy, Safety and Tolerability of ALKS 2680 in Adults With Narcolepsy Type 1 (Brilliance NT1 - 304)",[11],"Phase 3","RECRUITING","2026-08-26T02:17:38.215063Z","2026-05-29T15:36:40.191481Z",{"nct_id":16,"title":17,"phases":18,"status":12,"updated_at":19,"content_modified":20},"NCT07363720","A Trial of TAK-861 for the Treatment of Narcolepsy With Cataplexy",[11],"2026-08-26T02:19:27.519777Z","2026-05-05T02:43:27.427098Z",{"nct_id":22,"title":23,"phases":24,"status":12,"updated_at":26,"content_modified":27},"NCT07493265","A Study to Evaluate the Efficacy and Safety of E2086 in Adults With Narcolepsy",[25],"Phase 2","2026-08-26T02:19:17.380174Z","2026-05-29T15:36:40.189609Z"]